CT增强扫描中泛影葡胺与欧乃派克副反应的对比观察  

Comparison of side effects between diatrizoate meglumine and onipaque during enhancement CT scanning

作　　者：沙树贞[1] 张兰[1] 

机构地区：[1]滨州医学院附属医院,山东滨州256603

出　　处：《西部医学》2006年第3期351-352,共2页Medical Journal of West China

摘　　要：目的探讨CT增强扫描过程中离子型与非离子型造影剂的选择和造影剂毒副反应的防治。方法将CT增强扫描的1568例患者分为离子型造影剂组(76%泛影葡胺)925例和非离子型造影剂组(欧乃派克)643例,观察给药后毒副反应发生率及其程度。结果离子型造影剂组毒副反应发生率10.7%,非离子型造影剂组为1.1%(χ2=57.923,P=0.000)。离子型造影剂组2例出现重度毒副反应,经抢救获得成功。非离子型造影剂组仅1例出现中度毒副反应。结论非离子型造影剂的毒副反应发生率显著低于离子型造影剂,高危病例应选择非离子型造影剂进行CT增强扫描检查。应用造影剂过程中应严密观察有无毒副反应的发生,并及时做出相应处理。Objective To investigate the best choice of different contrast mediums and the prevention and management of side effects during enhancement CT scanning. Methods 1568 cases who needed enhancement CT scanning were divided into two groups, 925 of them received ionic contrast medium （diatrizoate meglumine） intravenously, whereas other 643 received non ionic medium（onipaque）. The occurrence and severity of side effects were observed and recorded. Results The incidence rate of side effects in ionic contrast me dium group was 10. 7%, whereas the nonionic group was 1.1% （X^2= 57. 923,P = 0. 000）. Conclusion The side effects are significantly lower in nonionic contrast medium group than ionic one. Nonionic contrast medium should be chosen for high risk cases. Close observation and timely management of side effects should be highlighted during enhancement CT scanning.

关 键 词：体层摄影术 X线计算机 造影剂 药物 副反应 

分 类 号：R814.43[医药卫生—影像医学与核医学] R965.3[医药卫生—放射医学]